Valuation — not yet established
No valuation for Curevo Vaccine is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($206.2M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Curevo Vaccine
Create free account
No card required
Funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Mar 2025 | Later Stage VC (Series B) | $110.0M | ▮ | ▮ |
| Nov 2022 | Later Stage VC (Series A1) | $26.0M | ▮ | ▮ |
| Feb 2022 | Later Stage VC (Series A) | $60.0M | ▮ | ▮ |
How Curevo Vaccine's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Curevo Vaccine, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Curevo Vaccine raised?
- Curevo Vaccine has raised $206.2M in total funding across 3 recorded rounds.
- When did Curevo Vaccine last raise?
- Curevo Vaccine last raised in Mar 2025 (Later Stage VC (Series B)), raising $110.0M.